Shrikant Akolkar
analystMale0.0Global Dominance: 0.00%
Shrikant Akolkar is a pharmaceutical industry analyst at Nuvama Institutional Equities. He has provided insights on the competitive pricing strategies of weight-loss drugs such as Wegovy and Mounjaro in India, highlighting the potential impact of generic drug manufacturers on the market once Wegovy's active ingredient goes off patent.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Shrikant Akolkar is a pharmaceutical industry analyst at Nuvama Institutional Equities who commented on the pricing of Wegovy.
Novo Nordisk launches weight-loss drug Wegovy in India to compete with Lilly’s Mounjaro - WorldDawn – Pakistan’s oldest and most widely read English daily, est. 1941·
Pakistan· 2025-06-24
Pakistan· 2025-06-24
